<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="128">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05159479</url>
  </required_header>
  <id_info>
    <org_study_id>140342</org_study_id>
    <nct_id>NCT05159479</nct_id>
  </id_info>
  <brief_title>Defining Robust Predictors of Chemotherapy Related Cardiotoxicity</brief_title>
  <official_title>Defining Robust Predictors of Chemotherapy Related Cardiotoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer affects 1 in 2 people during their life. Major improvements in cancer treatment mean&#xD;
      that many people are now living longer with cancer. But certain cancer drugs have the&#xD;
      potential to damage the heart and blood vessels. One type of cancer therapy called&#xD;
      fluoropyrimidines, is used in many cancers including bowel, breast, pancreatic and head and&#xD;
      neck. This chemotherapy can cause chest pain, heart attacks and abnormal heart rhythms in&#xD;
      approximately 10% of patients.&#xD;
&#xD;
      Adverse cardiac events lead to disruption of chemotherapy and can lead to adverse cancer&#xD;
      outcomes. Some patients will require alternative treatment. Most cardiac events occur during&#xD;
      the early cycles of treatment with fluoropyrimidines.&#xD;
&#xD;
      Currently, we do not know how to predict which patients are most likely to be affected.&#xD;
      Patients deemed to be at a high cardiovascular risk are often denied this treatment which is&#xD;
      first line for all gastrointestinal cancers. There is no hard evidence to support this&#xD;
      approach and patients may be inappropriately denied treatment.&#xD;
&#xD;
      If we were able to confidently identify patients at the highest risk, then we could&#xD;
      potentially reduce risk of toxicity by giving cardioprotective medications or we would be&#xD;
      able to confidently identify those who should be given alternative chemotherapy.&#xD;
&#xD;
      In this study, we will prospectively perform a cardiovascular risk assessment in patients&#xD;
      prior to initiation of chemotherapy using QRisk3. We will also perform baseline and serial&#xD;
      electrocardiography and cardiac biomarkers with troponin T. We will follow up our patients&#xD;
      for clinical cardiovascular events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adjudicated Cardiovascular events during fluoropyrimidine chemotherapy</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as:&#xD;
Types 1-3 myocardial infarction with troponin &gt;99th percentile upper limit,&#xD;
Incident myocardial ischaemia (chest pain with new inducible perfusion abnormality on perfusion cardiac MRI, --Myocarditis (diagnosed as per ESC Consensus statement&#xD;
Incident heart failure diagnosis (symptoms with NTproBNP &gt;400pg/ml or HF hospitalization),&#xD;
Incident arrhythmia (excluding isolated ectopy) or sudden cardiac death.</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Cardiotoxicity</condition>
  <condition>Gastrointestinal Neoplasms</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited from secondary or tertiary care centres from oncology clinics.&#xD;
        Patients included will be undergoing chemotherapy in the neoadjuvant, adjuvant and&#xD;
        palliative setting.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18&#xD;
&#xD;
          -  Consented to receive fluoropyrimidine chemotherapy for GI malignancies&#xD;
             (gastro-oesophageal, colorectal, pancreatic)&#xD;
&#xD;
          -  Capacity to provide consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18&#xD;
&#xD;
          -  Lacking capacity to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Aderonke Abiodun</last_name>
    <phone>07737138851</phone>
    <email>aderonketemilade.abiodun@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Bartholomews Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aderonke Abiodun</last_name>
      <email>aderonketemilade.abiodun@nhs.net</email>
    </contact>
    <contact_backup>
      <phone_ext>Manisty</phone_ext>
      <email>charlotte.manisty@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Charlotte Manisty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 1, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fluoropyrimidine</keyword>
  <keyword>Cardiotoxicity</keyword>
  <keyword>Cardio-oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

